Personalized Medicine Bulletin

Latest from Personalized Medicine Bulletin

Somatic mosaicisms are post-conception changes to cellular DNA that lead to genetic variation among cells in an organism. These changes can account for variation among individuals’ health or disease progression. Therefore, an understanding of their implication in disease response could lead to new personalized therapies.
In May of 2023, the National Institutes of Health (NIH)

The White House recently announced the Precision Surgery Initiative (PSI) as a “first-of-its kind Advanced Research Projects Agency for Health (ARPA-H) program to develop novel technologies” to more precisely excise cancerous growths to improve outcomes for cancer patients. July 27, 2023 White House Press Release (Release). PSI will add to the Cancer Moonshot’s arsenal of

Precision medicine was identified by a recent White House Office of Science and Technology Policy Report (“Report”) as a research and development priority for the United States over the next 20 years. The Report highlighted goals to advance precision medicine, including improvements in health monitoring, multi-omics, cell therapies, artificial intelligence-driven drug development, gene

The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022 milestones include progress in diagnostics, therapeutics and new treatment modalities.
1.  12 new drugs identified as personalized medicines were approved in

Precision or personalized medicine seeks to find the right treatment for each patient at the right time based on the patient’s genes, proteins and other personal characteristics. The approach has been successfully used to treat cancer. Indeed, many of the newly approved drugs in 2021 are cancer treatments.1
The USPTO initiated a Patents for Patients

The USPTO recently released a Report to Congress (“Report”) detailing the results of its call for public comments regarding the impact of U.S. jurisprudence on patent subject matter eligibility. The Report is responsive to requests from Senators Thom Tillis (R-NC), Chris Coons (D-DE), Mazie Hirono (D-HI), and Tom Cotton (R-AR) to collect information from the

Last week I reported on The Personalized Medicine Coalition’s (PMC) recently released PERSONALIZED MEDICINE AT FDA: The Scope & Significance of Progress in 2021 (2021 Report) that surveyed U.S. Food and Drug Administration (FDA)-approved personalized therapies. In addition to personalized therapies, the 2021 Report highlights the progress in diagnostic technologies. 
Diagnostic technologies are integral to

The Personalized Medicine Coalition (PMC) released PERSONALIZED MEDICINE AT FDA: The Scope & Significance of Progress in 2021 (2021 Report), its recent survey of U.S. Food and Drug Administration (FDA)-approved personalized therapies and diagnostic tests that enable those therapies. The 2021 Report highlights that personalized medicines accounted for over a third of new drug approvals

Artificial Intelligence (AI) has changed our lives. Improvements in data mining, personal and automotive navigation, cybersecurity, personal entertainment and healthcare are several examples of the impact of AI.[1] Recognizing that technological process can be measured by a review of the patent literature, the USPTO recently examined the patent literature from 1976 through 2018 to gauge

Does payer coverage of genomic testing drive utilization? That is the question The Personalized Medicine Coalition (“PMC”) asked and answered in its recent report “Understanding Genomic Testing Utilization and Coverage in the US” (“Study”). PMC’s Study, conducted in collaboration with BlueCross/BlueShield Association, Concert Genetics, and Illumina, sought to uncover patterns between the clinical